Sign In
29 Jul 2008 13:47
ο»Ώ
For Immediate Release
29 July 2008
ReGen Therapeutics PlcΒ (AIM: RGT)
Update on US International OTCQX trading platformΒ
ReGen Therapeutics Plc ("ReGen" or the "Company") announced on the 14thΒ July that its American Depository Receipts (ADRs) were trading on the US International OTCQX under the symbol REGUY. ReGen now confirms that it can issue ADRs in respect of up to 25% of its issued share capital. Each ADR represents 20 of ReGen ordinary shares. ReGen retains its primary listing onΒ AIM.
Further details of ReGen's ADR programme can be found at www.regentherapeutics.com/reganplc/investors/adr/
ENDS
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
RolandΒ Cornish/Felicity Geidt
BeaumontΒ Cornish
Tel No 020 7628 3396
David Scott/NickΒ Bealer
Alexander David
Tel No 020 7448 9800
AdrianΒ Duffield/Jon Davies
College Hill Associates
Tel No 020 7457 2020
Β Β
Notes to Editors:
About ReGen Therapeutics
ReGen TherapeuticsΒ PLCΒ is a UK-based biopharmaceutical company engaged in the acquisition and development of therapies related to age related disorders including Alzheimer's disease, Parkinson's disease and other degenerative neurological disorders.
The Company is focused particularly on technologies that address large unmet medical need to maintain healthy brain ageing, as well as rehabilitation after traumatic brain injury. ReGen's product pipeline comprises ColostrininTMΒ a nutraceutical that is in full commercial production and had been launched to the professional channel in the USA and Australia under the brand name CogniSureTM; a drug development programme based on ColostrininTM-derived peptides; and Phase II clinical trials on a novel formulation of Zolpidem for the treatment of brain trauma and reversal of dormancy.
About International OTCQX
International OTCQX provides a gateway toΒ U.S.Β securities markets for international companies that are listed on a qualified non-U.S. exchange and provide ongoing disclosure in English toΒ U.S.Β investors. More importantly, International OTCQX distinguishes the reputable international issuers from the 8,000 over-the-counter (OTC) securities traded in theΒ U.S.Β Only leading companies that have substantial operating businesses and provide credible disclosure to the public are eligible for inclusion on the premium-tier International OTCQX, which commenced trading onΒ March 5, 2007. For more about International OTCQX, visitΒ www.otcqx.com.Β
About Pink OTC Markets Inc.
Pink OTC Markets Inc. provides the leading inter-dealer electronic quotation and trading system in the over-the-counter (OTC) securities market. We create innovative technology and data solutions to efficiently connect market participants, improve price discovery, increase issuer disclosure, and better inform investors. Pink OTC Markets operates the third largestΒ U.S.Β equity trading venue which includes both the elite OTCQX market tiers for strong OTC-traded companies that can satisfyΒ financialΒ and disclosure listing standards and Pink Sheets for all other OTC quoted securities.
Over 230Β financialΒ service firms, including the ten largest U.S. investment banks, actively make markets in OTCQX and Pink Sheets quoted securities and in 2007 these firms traded over $160 billion of OTCQX and Pink Sheets securities. Pink OTC Markets offers widespread access to allΒ U.S.Β broker-dealers, enabling investors to seamlessly trade these securities through their institutional, online, or full service brokers.
Pink OTC Markets is headquartered inΒ New York City.
To learn more about how Pink OTC Markets' products and services make OTC markets more transparent, informed, and efficient, please visit our websites at www.pinksheets.com and www.otcqx.com or contact us atΒ info@pinkotc.com.'
Follow the stocks
